A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer

Rachel Kerslake; Marcia Hall; Paola Vagnarelli; Jeyarooban Jeyaneethi; Harpal S. Randeva; George Pados; Ioannis Kyrou; Emmanouil Karteris

doi:10.3892/ol.2021.12911

A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer

Rachel Kerslake
, Marcia Hall
, Paola Vagnarelli
, Jeyarooban Jeyaneethi
, Harpal S. Randeva
, George Pados
, Ioannis Kyrou^*
, Emmanouil Karteris^*

^*Corresponding author for this work

Aston Medical School

Brunel University
Mount Vernon Cancer Centre
University Hospitals Coventry
University of Warwick
University Campus
Harefield Hospital

Research output: Contribution to journal › Article › peer-review

29 Citations (SciVal)

17 Downloads (Pure)

Abstract

Ovarian cancer affects 295,000 women worldwide and is the most lethal of gynaecological malignancies. Often diagnosed at a late stage, current research efforts seek to further the molecular understanding of its aetiopathogenesis and the development of novel biomarkers. The present study investigated the expression levels of the glucogenic hormone asprosin [encoded by fibrillin-1 (FBN1)], and its cognate receptor, olfactory receptor 4M1 (OR4M1), in ovarian cancer. A blend of in silico open access The Cancer Genome Atlas data, as well as in vitro reverse transcription-quantitative PCR (RT-qPCR), immunohistochemistry and immunofluorescence data were used. RT-qPCR revealed expression levels of OR4M1 and FBN1 in clinical samples and in ovarian cancer cell lines (SKOV-3, PEO1, PEO4 and MDAH-2774), as well as the normal human ovarian surface epithelial cell line (HOSEpiC) . Immunohistochemical staining of a tissue microarray was used to identify the expression levels of OR4M1 and asprosin in ovarian cancer samples of varying histological subtype and grade, including clear cell carcinoma, serous ovarian cancer and mucinous adenocarcinoma. Immunofluorescence analysis revealed asprosin expression in SKOV-3 and HOSEpiC cells. These results demonstrated the expression of both asprosin and OR4M1 in normal and malignant human ovarian tissues. This research invokes further investigation to advance the understanding of the role of asprosin and OR4M1 within the ovarian tumour microenvironment.

Original language	English
Article number	650
Journal	Oncology Letters
Volume	22
Issue number	3
Early online date	9 Jul 2021
DOIs	https://doi.org/10.3892/ol.2021.12911
Publication status	Published - 1 Sept 2021

Bibliographical note

Copyright © Kerslake et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Funding: The present study was funded by Cancer Treatment & Research Trust and University Hospitals Coventry and Warwickshire NHS Trust (grant no. 12899).

Funding

The present study was funded by Cancer Treatment & Research Trust and University Hospitals Coventry and Warwickshire NHS Trust (grant no. 12899).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

asprosin
cancer
fibrillin-1
olfactory receptor
olfactory receptor 4M1
ovarian cancer

Access to Document

10.3892/ol.2021.12911Licence: CC BY 3.0

detailed expression profiling in ovarian cancer
Copyright © Kerslake et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Final published version, 5.19 MBLicence: CC BY 3.0

Cite this

@article{062c3700b9cb4f3a96866d80315a06e9,

title = "A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer",

abstract = "Ovarian cancer affects 295,000 women worldwide and is the most lethal of gynaecological malignancies. Often diagnosed at a late stage, current research efforts seek to further the molecular understanding of its aetiopathogenesis and the development of novel biomarkers. The present study investigated the expression levels of the glucogenic hormone asprosin [encoded by fibrillin-1 (FBN1)], and its cognate receptor, olfactory receptor 4M1 (OR4M1), in ovarian cancer. A blend of in silico open access The Cancer Genome Atlas data, as well as in vitro reverse transcription-quantitative PCR (RT-qPCR), immunohistochemistry and immunofluorescence data were used. RT-qPCR revealed expression levels of OR4M1 and FBN1 in clinical samples and in ovarian cancer cell lines (SKOV-3, PEO1, PEO4 and MDAH-2774), as well as the normal human ovarian surface epithelial cell line (HOSEpiC) . Immunohistochemical staining of a tissue microarray was used to identify the expression levels of OR4M1 and asprosin in ovarian cancer samples of varying histological subtype and grade, including clear cell carcinoma, serous ovarian cancer and mucinous adenocarcinoma. Immunofluorescence analysis revealed asprosin expression in SKOV-3 and HOSEpiC cells. These results demonstrated the expression of both asprosin and OR4M1 in normal and malignant human ovarian tissues. This research invokes further investigation to advance the understanding of the role of asprosin and OR4M1 within the ovarian tumour microenvironment.",

keywords = "asprosin, cancer, fibrillin-1, olfactory receptor, olfactory receptor 4M1, ovarian cancer",

author = "Rachel Kerslake and Marcia Hall and Paola Vagnarelli and Jeyarooban Jeyaneethi and Randeva, \{Harpal S.\} and George Pados and Ioannis Kyrou and Emmanouil Karteris",

note = "Copyright {\textcopyright} Kerslake et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0]. Funding: The present study was funded by Cancer Treatment \& Research Trust and University Hospitals Coventry and Warwickshire NHS Trust (grant no. 12899). ",

year = "2021",

month = sep,

day = "1",

doi = "10.3892/ol.2021.12911",

language = "English",

volume = "22",

journal = "Oncology Letters",

issn = "1792-1074",

publisher = "Spandidos Publications",

number = "3",

}

TY - JOUR

T1 - A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer

AU - Kerslake, Rachel

AU - Hall, Marcia

AU - Vagnarelli, Paola

AU - Jeyaneethi, Jeyarooban

AU - Randeva, Harpal S.

AU - Pados, George

AU - Kyrou, Ioannis

AU - Karteris, Emmanouil

N1 - Copyright © Kerslake et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0]. Funding: The present study was funded by Cancer Treatment & Research Trust and University Hospitals Coventry and Warwickshire NHS Trust (grant no. 12899).

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Ovarian cancer affects 295,000 women worldwide and is the most lethal of gynaecological malignancies. Often diagnosed at a late stage, current research efforts seek to further the molecular understanding of its aetiopathogenesis and the development of novel biomarkers. The present study investigated the expression levels of the glucogenic hormone asprosin [encoded by fibrillin-1 (FBN1)], and its cognate receptor, olfactory receptor 4M1 (OR4M1), in ovarian cancer. A blend of in silico open access The Cancer Genome Atlas data, as well as in vitro reverse transcription-quantitative PCR (RT-qPCR), immunohistochemistry and immunofluorescence data were used. RT-qPCR revealed expression levels of OR4M1 and FBN1 in clinical samples and in ovarian cancer cell lines (SKOV-3, PEO1, PEO4 and MDAH-2774), as well as the normal human ovarian surface epithelial cell line (HOSEpiC) . Immunohistochemical staining of a tissue microarray was used to identify the expression levels of OR4M1 and asprosin in ovarian cancer samples of varying histological subtype and grade, including clear cell carcinoma, serous ovarian cancer and mucinous adenocarcinoma. Immunofluorescence analysis revealed asprosin expression in SKOV-3 and HOSEpiC cells. These results demonstrated the expression of both asprosin and OR4M1 in normal and malignant human ovarian tissues. This research invokes further investigation to advance the understanding of the role of asprosin and OR4M1 within the ovarian tumour microenvironment.

AB - Ovarian cancer affects 295,000 women worldwide and is the most lethal of gynaecological malignancies. Often diagnosed at a late stage, current research efforts seek to further the molecular understanding of its aetiopathogenesis and the development of novel biomarkers. The present study investigated the expression levels of the glucogenic hormone asprosin [encoded by fibrillin-1 (FBN1)], and its cognate receptor, olfactory receptor 4M1 (OR4M1), in ovarian cancer. A blend of in silico open access The Cancer Genome Atlas data, as well as in vitro reverse transcription-quantitative PCR (RT-qPCR), immunohistochemistry and immunofluorescence data were used. RT-qPCR revealed expression levels of OR4M1 and FBN1 in clinical samples and in ovarian cancer cell lines (SKOV-3, PEO1, PEO4 and MDAH-2774), as well as the normal human ovarian surface epithelial cell line (HOSEpiC) . Immunohistochemical staining of a tissue microarray was used to identify the expression levels of OR4M1 and asprosin in ovarian cancer samples of varying histological subtype and grade, including clear cell carcinoma, serous ovarian cancer and mucinous adenocarcinoma. Immunofluorescence analysis revealed asprosin expression in SKOV-3 and HOSEpiC cells. These results demonstrated the expression of both asprosin and OR4M1 in normal and malignant human ovarian tissues. This research invokes further investigation to advance the understanding of the role of asprosin and OR4M1 within the ovarian tumour microenvironment.

KW - asprosin

KW - cancer

KW - fibrillin-1

KW - olfactory receptor

KW - olfactory receptor 4M1

KW - ovarian cancer

UR - https://www.scopus.com/pages/publications/85110369749

UR - https://www.spandidos-publications.com/10.3892/ol.2021.12911

U2 - 10.3892/ol.2021.12911

DO - 10.3892/ol.2021.12911

M3 - Article

AN - SCOPUS:85110369749

SN - 1792-1074

VL - 22

JO - Oncology Letters

JF - Oncology Letters

IS - 3

M1 - 650

ER -

A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this